Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders

References

• Berntzen HB, Fagerhol MK. L1, a major granulocyte protein: antigenic properties of its subunits. Scand J Clin Lab Invest 1988;48:647–52.
   PubMed Web of Science ®Google Scholar
• Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 2009;58:859–68.
   PubMed Web of Science ®Google Scholar
• Burri E, Beglinger C. Faecal calprotectin in the diagnosis of inflammatory bowel disease. Biochem Med (Zagreb) 2011;21:245–53.
   PubMed Web of Science ®Google Scholar
• Wildt S, Nordgaard Lassen I, Bendtsen F, Rumessen JJ. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol 2007;19:567–74.
   PubMed Web of Science ®Google Scholar
• Shastri YM, Bergis D, Povse N, Schafer V, Shastri S, Weindel M, et al. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am J Med 2008;121:1099–106.
   PubMed Web of Science ®Google Scholar
• Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjamason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenteroly 2005;128:1172–8.
   PubMed Web of Science ®Google Scholar
• Roseth AG, Kristinsson J, Fagerhol MK, Schjonsby H, Aadland E, Nygaard K, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993;28:1073–6.
   PubMed Web of Science ®Google Scholar
• Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess Andresen CF, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. J Clin Pathol 1997;50:113–23.
   Web of Science ®Google Scholar
• Schoepfer AM, Trummler M, Seeholzer P, Seibold Schmid B, Seibold F. Discriminating IBD from IBS: comparison of test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008;14:32–9.
   PubMed Web of Science ®Google Scholar
• Ton H, Brandsnes Dale S, Hotlund J, Skuibina F, Schjonsby H, et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41–54.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Park KS. Irritable bowel syndrome: Emerging paradigm in pathophysiology. World J Gastroenterol 2014;20:2456–69.
   PubMed Web of Science ®Google Scholar
• D’Incà R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, et al. Can Calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008;103:2007–14.
   PubMed Web of Science ®Google Scholar
• Fiehn AM, Bjørnbak C, Warnecke M, Engel PJ, Munck LK. Observer variability in the histopathologic diagnosis of microscopic colitis and subgroups. Hum Pathol 2013;44:2461–6.
   PubMed Web of Science ®Google Scholar
• Talley NJ. Irritable bowel syndrome: definition, diagnosis, and epidemiology. Bailleres Best Pract Res Clin Gastroenterol 1999;13:371–84.
   PubMed Web of Science ®Google Scholar
• Licata A, Randazzo C, Cappello M, Calvaruso V, Butera G, Florena AM, et al. Fecal calprotectin in clinical practice. A noninvasive screening tool for patients with chronic diarrhea. J Clin Gastroenterol 2012;46:504–8.
   PubMed Web of Science ®Google Scholar
• Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003;35:642–7.
   PubMedGoogle Scholar
• Berstad A, Arslan G, Folvik G. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid. Scand J Gastroenterol 2000;35:64–9.
   PubMed Web of Science ®Google Scholar
• Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778–83.
   PubMed Web of Science ®Google Scholar
• Cremon C, Gargano L, Morselli-Labate AM, Santini D, De Giorgio R, Stenghellini V, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009;104:392–400.
   PubMed Web of Science ®Google Scholar
• Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008;57:923–9.
   PubMed Web of Science ®Google Scholar
• Ohman L, Isaksson S, Lindmark AC, Posserud I, Stotzer PO, Strid H, et al. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 2009;104:1205–12.
   PubMed Web of Science ®Google Scholar
• Van Rheenen PF, Van de Vijer E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic mata-analysis. BMJ 2010;341:c3369.
   PubMed Web of Science ®Google Scholar